BetterLife Pharma plans private placement outside Canada alongside share, warrant offering

• BetterLife Pharma filed a preliminary prospectus for a marketed offering of common shares or pre-funded warrants in Canada.
• Securities are also expected to be sold via private placement in certain jurisdictions outside Canada under local securities laws.
• Deal size, pricing, share count remain undecided pending negotiations with agents Bloom Burton Securities, Haywood Securities.
• Net proceeds earmarked for early-stage clinical studies targeting cluster headache, migraine, working capital.
• Closing targeted for about Sept. 15, 2026, subject to definitive agency agreement, customary conditions, CSE approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608241842NEWSFILECNPR____20260824_311170_1) on August 24, 2026, and is solely responsible for the information contained therein.